NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vima Therapeutics

Vima Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://vimatx.com/

Last Round

Series A

Mar 11, 2026

Total Funding Raised

$140M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vima Therapeutics is a biotechnology company developing oral therapeutics designed for the treatment of movement disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverymovement disorderssmall-molecule therapyclinical trialsdystoniaParkinson's diseasebiotechneurologyoral therapypharmaclinical-stagedrug developmentmotor control

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vima Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Vima Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vima Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 11, 2026
Series AMay 29, 2025
View all Funding Rounds

Key People

Founding team and executive leadership

Bernard Ravina

Chief Executive Officer

Executive Team

Vima Therapeutics Investors

Notable investors and investment history

Vima Therapeutics investors
InvestorRounds
Access IndustriesSeries A
Frazier Life SciencesSeries A
Canaan PartnersSeries A
Atlas VentureSeries A, Seed
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2026

    Grew 16% QoQ, from 19 to 22 employees.

  • Apr 24, 2026

    Monthly visitors increased 303% MoM, reaching 2.4K.

View all signals

Vima Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vima Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vima Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range23
Year Founded2023
Last FundingMar 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.